Karyopharm Therapeutics (KPTI) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

KPTI Stock Forecast

Karyopharm Therapeutics stock forecast is as follows: an average price target of $7.33 (represents a 1054.33% upside from KPTI’s last price of $0.64) and a rating consensus of 'Buy', based on 4 wall street analysts offering a 1-year stock forecast.

KPTI Price Target

The average price target for Karyopharm Therapeutics (KPTI) is $7.33 based on 1-year price targets from 4 Wall Street analysts in the past 3 months, with a price target range of $14.00 to $3.00. This represents a potential 1054.33% upside from KPTI's last price of $0.64.

KPTI Analyst Ratings

Buy

According to 4 Wall Street analysts, Karyopharm Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for KPTI stock is 0 'Strong Buy' (0.00%), 3 'Buy' (75.00%), 1 'Hold' (25.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Karyopharm Therapeutics Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Jun 10, 2024	Brian Abrahams	RBC Capital	$3.00	$0.95	215.42%	372.44%
Jan 10, 2023		Leerink Partners	$5.00	$2.84	76.06%	687.40%
Aug 23, 2022	Collen Kusy	Robert W. Baird	$14.00	$5.56	151.80%	2104.72%
Mar 10, 2022	Brian Abrahams	RBC Capital	$8.00	$6.49	23.27%	1159.84%

The latest Karyopharm Therapeutics stock forecast, released on Jun 10, 2024 by Brian Abrahams from RBC Capital, set a price target of $3.00, which represents a 215.42% increase from the stock price at the time of the forecast ($0.95), and a 372.44% increase from KPTI last price ($0.64).

Karyopharm Therapeutics Price Target by Period

	1M	3M	12M
# Anlaysts	-	-	1
Avg Price Target	-	-	$3.00
Last Closing Price	$0.64	$0.64	$0.64
Upside/Downside	-100.00%	-100.00%	372.44%

In the current month, the average price target of Karyopharm Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Karyopharm Therapeutics's last price of $0.64. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Nov 06, 2024	Piper Sandler	Overweight	Overweight	Hold
Jul 01, 2024	H.C. Wainwright	Buy	Buy	Hold
Jun 10, 2024	RBC Capital	Outperform	Outperform	Hold
Jan 10, 2023	SVB Leerink	Market Perform	Market Perform	Hold
Nov 04, 2022	RBC Capital	Sector Perform	Outperform	Upgrade
Mar 10, 2022	RBC Capital	Sector Perform	Sector Perform	Hold

Karyopharm Therapeutics's last stock rating was published by Piper Sandler on Nov 06, 2024. The company gave KPTI a "Overweight" rating, the same as its previous rate.

Karyopharm Therapeutics Financial Forecast

Karyopharm Therapeutics Revenue Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17
Revenue	-	-	-	-	-	-	-	-	-	$36.01M	$37.58M	$38.70M	$33.58M	$36.15M	$39.68M	$47.67M	$126.27M	$37.69M	$22.60M	$23.26M	$35.10M	$21.33M	$33.51M	$18.14M	$18.10M	$13.15M	$9.49M	$155.00K	$10.00M	$68.00K
Avg Forecast	$50.30M	$49.60M	$49.50M	$45.70M	$38.21M	$37.92M	$36.21M	$34.48M	$35.40M	$37.27M	$35.67M	$36.32M	$34.43M	$34.83M	$35.96M	$34.41M	$52.71M	$26.21M	$26.30M	$25.89M	$28.61M	$23.02M	$28.41M	$21.47M	$16.34M	$2.77M	$106.00K	$364.56K	$7.95M	$64.17K
High Forecast	$51.14M	$50.43M	$50.33M	$46.46M	$40.86M	$38.02M	$36.21M	$34.48M	$36.00M	$37.27M	$36.27M	$36.93M	$35.00M	$34.83M	$35.96M	$34.41M	$52.71M	$26.21M	$26.30M	$25.89M	$28.61M	$23.02M	$28.41M	$21.47M	$16.34M	$2.77M	$106.00K	$364.56K	$9.54M	$77.00K
Low Forecast	$49.19M	$48.51M	$48.41M	$44.69M	$35.78M	$37.83M	$36.21M	$34.48M	$34.63M	$37.27M	$34.89M	$35.52M	$33.67M	$34.83M	$35.96M	$34.41M	$52.71M	$26.21M	$26.30M	$25.89M	$28.61M	$23.02M	$28.41M	$21.47M	$16.34M	$2.77M	$106.00K	$364.56K	$6.36M	$51.33K
# Analysts	1	1	1	1	5	4	1	1	3	1	1	1	1	1	1	1	1	1	1	1	9	8	7	6	5	5	5	5	13	12
Surprise %	-	-	-	-	-	-	-	-	-	0.97%	1.05%	1.07%	0.98%	1.04%	1.10%	1.39%	2.40%	1.44%	0.86%	0.90%	1.23%	0.93%	1.18%	0.84%	1.11%	4.74%	89.56%	0.43%	1.26%	1.06%

Karyopharm Therapeutics's average Quarter revenue forecast for Dec 23 based on 3 analysts is $35.40M, with a low forecast of $34.63M, and a high forecast of $36.00M. KPTI's average Quarter revenue forecast represents a -1.68% decrease compared to the company's last Quarter revenue of $36.01M (Sep 23).

Karyopharm Therapeutics EBITDA Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17
# Analysts	1	1	1	1	5	4	1	1	3	1	1	1	1	1	1	1	1	1	1	1	9	8	7	6	5	5	5	5	13	12
EBITDA	-	-	-	-	-	-	-	-	-	$-31.26M	$-29.57M	$-28.31M	$-32.55M	$-30.16M	$-42.48M	$-34.41M	$46.68M	$-43.51M	$-48.22M	$-51.94M	$-36.03M	$-46.41M	$-39.29M	$-46.11M	$-41.68M	$-38.01M	$-40.08M	$-62.91M	$-38.28M	$-29.71M
Avg Forecast	$-41.85M	$-41.27M	$-41.18M	$-38.02M	$-31.79M	$-31.55M	$-30.13M	$-41.01M	$-29.46M	$-31.01M	$-29.68M	$-37.28M	$-28.64M	$-29.54M	$-30.50M	$-39.87M	$-44.70M	$-22.23M	$-22.30M	$-47.55M	$-24.26M	$-19.52M	$-24.10M	$-40.10M	$-13.86M	$-2.35M	$-89.89K	$-47.00M	$-28.40M	$-27.94M
High Forecast	$-40.93M	$-40.36M	$-40.28M	$-37.19M	$-29.77M	$-31.47M	$-30.13M	$-32.80M	$-28.81M	$-31.01M	$-29.03M	$-29.82M	$-28.01M	$-29.54M	$-30.50M	$-31.90M	$-44.70M	$-22.23M	$-22.30M	$-38.04M	$-24.26M	$-19.52M	$-24.10M	$-32.08M	$-13.86M	$-2.35M	$-89.89K	$-37.60M	$-22.72M	$-22.35M
Low Forecast	$-42.55M	$-41.96M	$-41.87M	$-38.66M	$-34.00M	$-31.63M	$-30.13M	$-49.21M	$-29.95M	$-31.01M	$-30.17M	$-44.73M	$-29.12M	$-29.54M	$-30.50M	$-47.84M	$-44.70M	$-22.23M	$-22.30M	$-57.06M	$-24.26M	$-19.52M	$-24.10M	$-48.12M	$-13.86M	$-2.35M	$-89.89K	$-56.40M	$-34.08M	$-33.52M
Surprise %	-	-	-	-	-	-	-	-	-	1.01%	1.00%	0.76%	1.14%	1.02%	1.39%	0.86%	-1.04%	1.96%	2.16%	1.09%	1.49%	2.38%	1.63%	1.15%	3.01%	16.17%	445.82%	1.34%	1.35%	1.06%

1 analysts predict KPTI's average Quarter EBITDA for Mar 22 to be $-39.87M, with a high of $-31.90M and a low of $-47.84M. This is -185.41% lower than Karyopharm Therapeutics's previous annual EBITDA (Dec 21) of $46.68M.

Karyopharm Therapeutics Net Income Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17
# Analysts	1	1	1	1	5	4	1	1	3	1	1	1	1	1	1	1	1	1	1	1	9	8	7	6	5	5	5	5	13	12
Net Income	-	-	-	-	-	-	-	-	-	$-34.51M	$-32.63M	$-34.13M	$-38.51M	$-36.32M	$-49.06M	$-41.40M	$38.72M	$-51.81M	$-53.58M	$-57.41M	$-43.42M	$-53.49M	$-46.43M	$-52.93M	$-48.65M	$-41.37M	$-43.41M	$-66.16M	$-38.46M	$-29.92M
Avg Forecast	$-23.75M	$-22.50M	$-20.00M	$-25.00M	$-30.89M	$-32.86M	$-37.24M	$-49.34M	$-38.75M	$-35.00M	$-42.78M	$-44.85M	$110.58M	$-87.34M	$-97.80M	$-47.97M	$-69.88M	$-103.98M	$-115.05M	$-52.56M	$-91.42M	$-108.56M	$-89.72M	$-46.03M	$-103.46M	$-127.59M	$-151.98M	$-49.43M	$-28.53M	$-28.13M
High Forecast	$-23.07M	$-21.86M	$-19.43M	$-24.29M	$-23.48M	$-31.92M	$-36.17M	$-39.47M	$-34.74M	$-34.00M	$-41.56M	$-35.88M	$132.69M	$-87.34M	$-97.80M	$-38.38M	$-69.88M	$-103.98M	$-115.05M	$-42.05M	$-91.42M	$-108.56M	$-89.72M	$-36.82M	$-103.46M	$-127.59M	$-151.98M	$-39.54M	$-22.83M	$-22.50M
Low Forecast	$-24.27M	$-22.99M	$-20.44M	$-25.54M	$-37.07M	$-33.57M	$-38.04M	$-59.20M	$-44.10M	$-35.76M	$-43.71M	$-53.82M	$88.46M	$-87.34M	$-97.80M	$-57.56M	$-69.88M	$-103.98M	$-115.05M	$-63.07M	$-91.42M	$-108.56M	$-89.72M	$-55.23M	$-103.46M	$-127.59M	$-151.98M	$-59.32M	$-34.24M	$-33.76M
Surprise %	-	-	-	-	-	-	-	-	-	0.99%	0.76%	0.76%	-0.35%	0.42%	0.50%	0.86%	-0.55%	0.50%	0.47%	1.09%	0.47%	0.49%	0.52%	1.15%	0.47%	0.32%	0.29%	1.34%	1.35%	1.06%

Karyopharm Therapeutics's average Quarter net income forecast for Mar 22 is $-47.97M, with a range of $-57.56M to $-38.38M. KPTI's average Quarter net income forecast represents a -223.89% decrease compared to the company's last Quarter net income of $38.72M (Dec 21).

Karyopharm Therapeutics SG&A Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17
# Analysts	1	1	1	1	5	4	1	1	3	1	1	1	1	1	1	1	1	1	1	1	9	8	7	6	5	5	5	5	13	12
SG&A	-	-	-	-	-	-	-	-	-	$30.80M	$34.48M	$35.91M	$34.65M	$34.65M	$37.34M	$38.77M	$34.56M	$35.10M	$36.53M	$37.65M	$33.93M	$30.97M	$30.84M	$30.68M	$28.39M	$25.27M	$24.66M	$27.10M	$7.62M	$6.26M
Avg Forecast	$62.99M	$62.12M	$61.99M	$57.23M	$47.85M	$47.50M	$45.35M	$43.18M	$44.34M	$46.68M	$44.67M	$45.48M	$43.12M	$43.62M	$45.04M	$43.09M	$66.02M	$32.83M	$32.94M	$32.43M	$35.83M	$28.83M	$35.58M	$26.88M	$20.46M	$3.47M	$132.75K	$456.56K	$5.65M	$80.36K
High Forecast	$64.05M	$63.16M	$63.03M	$58.19M	$51.17M	$47.62M	$45.35M	$43.18M	$45.08M	$46.68M	$45.42M	$46.24M	$43.84M	$43.62M	$45.04M	$43.09M	$66.02M	$32.83M	$32.94M	$32.43M	$35.83M	$28.83M	$35.58M	$26.88M	$20.46M	$3.47M	$132.75K	$456.56K	$6.79M	$96.43K
Low Forecast	$61.61M	$60.75M	$60.63M	$55.98M	$44.81M	$47.38M	$45.35M	$43.18M	$43.37M	$46.68M	$43.69M	$44.48M	$42.17M	$43.62M	$45.04M	$43.09M	$66.02M	$32.83M	$32.94M	$32.43M	$35.83M	$28.83M	$35.58M	$26.88M	$20.46M	$3.47M	$132.75K	$456.56K	$4.52M	$64.29K
Surprise %	-	-	-	-	-	-	-	-	-	0.66%	0.77%	0.79%	0.80%	0.79%	0.83%	0.90%	0.52%	1.07%	1.11%	1.16%	0.95%	1.07%	0.87%	1.14%	1.39%	7.28%	185.77%	59.36%	1.35%	77.95%

Karyopharm Therapeutics's average Quarter SG&A projection for Dec 23 is $44.34M, based on 3 Wall Street analysts, with a range of $43.37M to $45.08M. The forecast indicates a 43.94% rise compared to KPTI last annual SG&A of $30.80M (Sep 23).

Karyopharm Therapeutics EPS Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17
# Analysts	1	1	1	1	5	4	1	1	3	1	1	1	1	1	1	1	1	1	1	1	9	8	7	6	5	5	5	5	13	12
EPS	-	-	-	-	-	-	-	-	-	$-0.30	$-0.29	$-0.30	$-0.43	$-0.45	$-0.62	$-0.53	$0.51	$-0.69	$-0.71	$-0.77	$-0.59	$-0.73	$-0.63	$-0.78	$-0.76	$-0.67	$-0.71	$-1.09	$-0.78	$-0.71
Avg Forecast	$-0.19	$-0.18	$-0.16	$-0.20	$-0.25	$-0.26	$-0.30	$-0.33	$-0.31	$-0.28	$-0.34	$-0.37	$-0.35	$-0.57	$-0.63	$-0.63	$-0.45	$-0.67	$-0.74	$-0.71	$-0.59	$-0.70	$-0.58	$-0.69	$-0.67	$-0.83	$-0.98	$-0.87	$-0.46	$-0.63
High Forecast	$-0.18	$-0.17	$-0.16	$-0.19	$-0.19	$-0.26	$-0.29	$-0.32	$-0.28	$-0.27	$-0.33	$-0.36	$-0.34	$-0.57	$-0.63	$-0.63	$-0.45	$-0.67	$-0.74	$-0.71	$-0.59	$-0.70	$-0.58	$-0.69	$-0.67	$-0.83	$-0.98	$-0.87	$-0.37	$-0.50
Low Forecast	$-0.19	$-0.18	$-0.16	$-0.20	$-0.30	$-0.27	$-0.30	$-0.34	$-0.35	$-0.29	$-0.35	$-0.38	$-0.36	$-0.57	$-0.63	$-0.63	$-0.45	$-0.67	$-0.74	$-0.71	$-0.59	$-0.70	$-0.58	$-0.69	$-0.67	$-0.83	$-0.98	$-0.87	$-0.55	$-0.76
Surprise %	-	-	-	-	-	-	-	-	-	1.07%	0.85%	0.82%	1.22%	0.80%	0.98%	0.84%	-1.13%	1.02%	0.95%	1.09%	1.00%	1.04%	1.08%	1.12%	1.13%	0.81%	0.72%	1.25%	1.70%	1.13%

According to 1 Wall Street analysts, Karyopharm Therapeutics's projected average Quarter EPS for Mar 22 is $-0.63, with a low estimate of $-0.63 and a high estimate of $-0.63. This represents a -223.73% decrease compared to KPTI previous annual EPS of $0.51 (Dec 21).

Karyopharm Therapeutics Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
KPTI	Karyopharm Therapeutics	$0.67	$7.33	994.03%	Buy
XFOR	X4 Pharmaceuticals	$0.74	$3.67	395.95%	Buy
GOSS	Gossamer Bio	$0.87	$3.75	331.03%	Buy
PMVP	PMV Pharmaceuticals	$1.52	$6.00	294.74%	Buy
ABOS	Acumen Pharmaceuticals	$1.96	$7.00	257.14%	Buy
CTMX	CytomX Therapeutics	$1.13	$3.47	207.08%	Buy
LYRA	Lyra Therapeutics	$0.18	$0.50	177.78%	Hold
NUVB	Nuvation Bio	$2.81	$7.00	149.11%	Buy
ASMB	Assembly Biosciences	$14.28	$35.50	148.60%	Buy
MREO	Mereo BioPharma Group	$3.40	$8.00	135.29%	Buy
REPL	Replimune Group	$11.72	$19.00	62.12%	Buy
BLUE	bluebird bio	$8.97	$13.69	52.62%	Hold
MRSN	Mersana Therapeutics	$2.03	$3.00	47.78%	Buy
HOOK	HOOKIPA Pharma	$2.13	$3.00	40.85%	Buy
AGIO	Agios Pharmaceuticals	$41.96	$53.50	27.50%	Buy
KRON	Kronos Bio	$0.96	$1.00	4.17%	Buy

KPTI Forecast FAQ

Is Karyopharm Therapeutics a good buy?

Yes, according to 4 Wall Street analysts, Karyopharm Therapeutics (KPTI) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 75.00% of KPTI's total ratings.

What is KPTI's price target?

Karyopharm Therapeutics (KPTI) average price target is $7.33 with a range of $3 to $14, implying a 1054.33% from its last price of $0.635. The data is based on 4 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Karyopharm Therapeutics stock go up soon?

According to Wall Street analysts' prediction for KPTI stock, the company can go up by 1054.33% (from the last price of $0.635 to the average price target of $7.33), up by 2104.72% based on the highest stock price target, and up by 372.44% based on the lowest stock price target.

Can Karyopharm Therapeutics stock reach $1?

KPTI's average twelve months analyst stock price target of $7.33 supports the claim that Karyopharm Therapeutics can reach $1 in the near future.

What are Karyopharm Therapeutics's analysts' financial forecasts?

Karyopharm Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $146.82M (high $149.57M, low $144.3M), average EBITDA is $-134M (high $-124M, low $-145M), average net income is $-150M (high $-131M, low $-168M), average SG&A $183.88M (high $187.32M, low $180.71M), and average EPS is $-1.142 (high $-1.057, low $-1.211). KPTI's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $195.1M (high $198.36M, low $190.81M), average EBITDA is $-162M (high $-159M, low $-165M), average net income is $-91.257M (high $-88.647M, low $-93.24M), average SG&A $244.34M (high $248.42M, low $238.97M), and average EPS is $-0.73 (high $-0.709, low $-0.746).

Did the KPTI's actual financial results beat the analysts' financial forecasts?

Based on Karyopharm Therapeutics's last annual report (Dec 2023), the company's revenue was $146.03M, beating the average analysts forecast of $144.67M by 0.94%. Apple's EBITDA was $-130M, beating the average prediction of $-127M by 1.66%. The company's net income was $-143M, missing the average estimation of $-161M by -11.33%. Apple's SG&A was $131.88M, missing the average forecast of $181.18M by -27.21%. Lastly, the company's EPS was $-1.25, missing the average prediction of $-1.3 by -3.82%. In terms of the last quarterly report (Sep 2023), Karyopharm Therapeutics's revenue was $36.01M, missing the average analysts' forecast of $37.27M by -3.39%. The company's EBITDA was $-31.26M, beating the average prediction of $-31.01M by 0.81%. Karyopharm Therapeutics's net income was $-34.506M, missing the average estimation of $-35.003M by -1.42%. The company's SG&A was $30.8M, missing the average forecast of $46.68M by -34.01%. Lastly, the company's EPS was $-0.3, beating the average prediction of $-0.28 by 7.14%